

1 **Incidence and prevalence of polymyxin resistant bacterial strains in the**
2 **clinical and environmental samples in India: a systematic review and meta-**
3 **analysis**

4

5 **Sambit K. Dwibedy^{1,3}, Indira Padhy¹, Aditya K. Panda^{1,2}, Saswat S. Mohapatra^{1,2*}**

6

7 ¹Department of Biotechnology, Berhampur University, Bhanja Bihar, Berhampur- 760007,
8 Odisha, India

9 ²Centre of Excellence on Bioprospecting of Ethno-pharmaceuticals of Southern Odisha
10 (CoE-BESO), Berhampur University, Bhanja Bihar, Berhampur- 760007, India

11 ³Department of Zoology, SBRG Women's College, Berhampur- 760001, Odisha, India

12

13 For Correspondence- saswatsmohapatra@gmail.com

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28 **Abstract**

29 **Introduction:** Polymyxins, the cationic lipopeptide antibiotics, are the last line of
30 therapeutics against the multi-drug resistant (MDR) pathogenic Gram-negative bacteria.
31 Unfortunately, the rising cases of polymyxin-resistant strains from across the globe have
32 adversely impacted the available treatment options. While the molecular mechanisms
33 responsible for developing polymyxin resistance (Pol^R) are largely understood, the
34 prevalence of Pol^R strains in India is not investigated systematically.

35 **Method:** For this study, a systematic search for relevant articles was performed in the
36 applicable databases for the period January 2015 to December 2023. A meta-analysis was
37 performed using the comprehensive meta-analysis software (V.4) to determine the overall
38 prevalence of Pol^R bacterial strains in India. Publication biases were assessed using funnel
39 plots and Egger's regression analysis.

40 **Result:** Considering a total of 43 studies selected based on the relevant inclusion and
41 exclusion criteria, the present meta-analysis found the rate of Pol^R bacteria in India to be at
42 15.7%, which is higher than the global average. Among the Indian States, Tamil Nadu topped
43 with the highest prevalence of Pol^R at 32.4%. Investigating the contribution of the mobile
44 colistin resistance (*mcr*) genes, it was observed that among the Pol^R strains, 8.6 % were *mcr*
45 positive.

46 **Conclusion:** The *mcr*-positive strains reported from India could be an underestimation of the
47 actual numbers due to the non-inclusion of *mcr* screening in many previous studies. Our
48 study provides insight into the state of the Pol^R situation in India, which may be useful to
49 develop a monitoring strategy to contain the spread of such strains and preserve the potency
50 of the polymyxins.

51

52 **Keywords:** Polymyxin resistance, colistin resistance, *mcr*, India, meta-analysis

53

54

55 INTRODUCTION

56 The significant use of antibiotics in healthcare, and agriculture, and their indiscriminate
57 prophylactic consumption has driven the rise of antibiotic-resistant bacterial pathogens.
58 Infections caused by antibiotic-resistant bacteria are increasingly becoming fatal due to the
59 non-availability of potent antibiotics against them. As per an estimate, drug-resistant
60 pathogens caused 4.95 million deaths in 2019 ¹, predicted to rise to 10 million deaths
61 annually by 2050 ². Considering the significant economic consequences of rising drug-
62 resistant infections, urgent mitigation measures are warranted.

63 Antibiotic-resistant bacteria belonging to the Gram-negative type pose a significant challenge
64 to treatment as increasing reports of resistance to third and fourth generations of
65 cephalosporins are reported globally ³. In this unprecedented situation, polymyxins, a group
66 of cationic peptide antibiotics, remain the last option for treatment ^{4,5}. Polymyxin was
67 initially isolated in 1947 from a soil bacterium *Paenibacillus polymyxa* ⁶ and approved for
68 clinical use in 1959 against Gram-negative bacteria. Due to their nephrotoxic and neurotoxic
69 properties, polymyxins were prohibited for clinical use in the 1970s ^{7,8} and were consequently
70 substituted by aminoglycosides, quinolones, and β -lactams. However, with the rising
71 infections caused by multi-drug resistant (MDR) Gram-negative bacteria (GNB) such as
72 *Klebsiella pneumoniae*, *Acinetobacter baumannii*, and *Pseudomonas aeruginosa*, and failure
73 of the frontline antibiotics, polymyxins have re-emerged albeit with some modifications in
74 the chemical structure as the last-resort antibiotic option against GNB ^{4,9}.

75 Polymyxins are of five types (polymyxin A to polymyxin E), of which colistin (polymyxin E)
76 and polymyxin B are approved for clinical use ¹⁰. Structurally, polymyxins are cationic
77 decapeptides consisting of a central cyclic heptapeptide with a tripeptide side-chain acylated
78 at the N-terminus by a fatty acid tail ^{11,12}. The primary target of cationic polymyxin is the
79 negatively charged outer membrane (OM) of GNB. Polymyxin destabilizes the OM
80 lipopolysaccharide (LPS) by displacing the divalent cations Mg^{2+} and Ca^{2+} resulting in
81 enhanced permeability of the membrane and leading to leakage of cytoplasmic content that
82 ultimately causes cell death ^{5,13,14}.

83 The extensive use of polymyxins in the preceding decade in both healthcare and animal feeds
84 has triggered the emergence of polymyxin-resistant (Pol^R) bacterial strains across the globe.
85 Pol^R bacterial species such as *K. pneumoniae* ¹⁵⁻¹⁷, *P. aeruginosa* ^{4,18}, *A. baumannii* ¹⁹, *E. coli*
86 ²⁰, *Shigella sonnei* ²¹, *Salmonella enterica* ²², *Enterobacter aerogenes* and *Enterobacter*

87 *cloacae*²³ have been reported from different parts of the world that have adversely affected
88 the healthcare sectors. Moreover, the detection of Pol^R GNB in both clinical and
89 environmental samples has made the situation alarming.

90 The primary mechanism responsible for Pol^R development is the remodelling of the OM in
91 GNB making it increasingly positive [by the addition of 4-amino-4-deoxy L-arabinose (L-
92 Ara4N) or phosphoethanolamine (pEtN)], leading to the repulsion of cationic polymyxins^{4,13}.
93 The OM remodelling is generally carried out by bacterial two-component signal transduction
94 systems (TCS). TCS generally sense the environmental cues and signal appropriately to
95 modulate the expression of genes involved in the response mechanisms. PhoPQ and PmrAB
96 are the two primary TCSs in the GNB involved in the OM remodelling in response to various
97 stresses including polymyxin treatment^{5,13}. Apart from PhoPQ and PmrAB TCSs, there are
98 several other such systems reported in various bacterial species^{14,24,25}. Though organisms can
99 develop resistance to polymyxins via TCS, there are many GNBs like *Serratia marcescens*,
100 *Proteus mirabilis*, *Proteus penneri*, *Proteus vulgaris*, *Providencia rettgeri*, *Providencia*
101 *stuartii*, *Vibrio cholerae*, *Campylobacter spp.*, *Legionella spp.*, *Morganella morganii*,
102 *Burkholderia spp.*, *Edwardsiella spp.*, *Aeromonas jandaei*, *Aeromonas hydrophila*,
103 *Acinetobacter junii*, *Neisseria spp.* that are naturally resistant to polymyxins due to the
104 constitutive expression of the *arnBCADTEF* operon and/or the *eptB* gene, which increase the
105 charge of LPS by addition of pEtN and/or L-Ara4N^{4,26}. Moreover, all Gram-positive and
106 anaerobic bacteria are also inherently resistant to polymyxins.

107 Though chromosome-encoded polymyxin resistance is the prevalent mechanism, the
108 detection of the plasmid-borne mobile colistin resistance (*mcr*) gene from the bacteria *E. coli*
109 and *K. pneumoniae* in China has made the situation alarming²⁰. The *mcr* gene encodes a
110 pEtN transferase enzyme that catalyses the addition of a pEtN residue to lipid-A moiety
111 which alters the net charge of the LPS reducing the binding of polymyxin. To date, ninety-
112 eight *mcr* alleles have been discovered belonging to ten different classes of *mcr* genes (*mcr*-1
113 to *mcr*-10) among many GNB pathogens. Bacterial plasmids bearing the *mcr* genes have been
114 reported from across the globe. Moreover, the different *mcr* classes have shown distinct
115 geographical distribution^{27,28}. As the potential of rapid dissemination of plasmid-borne *mcr*
116 genes is significantly high, it is pertinent to conduct periodic surveillance to monitor their
117 distribution in the environment and clinic.

118 In the Indian context, *mcr* genes have been reported in several studies conducted using
119 clinical samples²⁹, hospital sewage³⁰, urban sewage water³¹, and food samples³². However,

120 a comprehensive analysis of the distribution of *mcr* genes across India is lacking. It is
121 important to highlight that the increasing number of carbapenem-resistant pathogenic bacteria
122 has made India one of the top users of polymyxins in the clinic. Furthermore, the use of
123 colistin as a growth promoter in poultry farms has triggered the spread of Pol^R GNB in the
124 environment. Though the Govt. of India has banned the use of colistin in farm animals since
125 2019, the impact of their extensive use before 2019 is yet to be assessed. Very few
126 investigations have been carried out in the Indian context, especially using environmental
127 samples to understand the dynamics of Pol^R bacterial strains in the environment and the
128 incidence of *mcr*-positive bacterial strains from across India.

129 The current meta-analysis was performed to determine the pattern and spread of Pol^R
130 bacterial strains in India and to find a correlation between Pol^R and the presence of the *mcr*
131 genes.

132 **MATERIALS & METHODS**

133 Using published articles, the present study was conducted to determine the prevalence and
134 spread of Pol^R Gram-negative bacteria (GNB) from clinical and environmental sources in
135 India and the contribution of *mcr* genes in gaining the resistance phenotype. The study was
136 undertaken as per the guidelines of Systematic Reviews and Meta-analyses (PRISMA) ³³
137 (Fig. 1).

138 **Data collection**

139 Databases like PubMed, Google Scholar, Science Direct, and Scopus were extensively
140 searched using the keywords “polymyxin resistance”, “colistin resistance”, “mobile colistin
141 resistance gene” and “India”. Original research articles with reports of Pol^R bacteria from
142 India, published between January 2015 to December 2023 were included in this study. The
143 last search was performed on January 06, 2024.

144 **Inclusion criteria**

145 For the meta-analysis, we only included articles that met the following requirements: 1) the
146 samples used in the studies must hail from India, 2) data on resistance to polymyxin B and/or
147 colistin must be available, 3) broth-microdilution (BMD) method must have been followed to
148 determine Pol^R of the bacterial isolates, 4) the article must mention the total sample size and
149 the number of Pol^R strains isolated or the prevalence frequency, and 5) the article must have
150 been published in English.

151 **Exclusion criteria**

152 The following exclusion criteria were strictly followed: 1) studies with no Pol^R isolate were
153 excluded from this analysis; 2) studies conducted outside India were not considered; 3)
154 studies that employed resistance detection methods other than BMD were disregarded; 4)
155 studies that were not published in English, were not peer-reviewed, and were published
156 before 2015 were excluded.

157 **Data extraction**

158 Data were extracted from relevant articles that were qualified based on the study's inclusion
159 and exclusion criteria (Fig. 1). Each report was individually screened and investigated for
160 eligibility by two different authors (SKD and IP). Following a thorough review, the following
161 information was extracted and summarised for each study: first author name, publication
162 year, State, or UT (Union Territories) of occurrence, total sample size, the total number of
163 Pol^R isolates, reported Pol^R bacteria, resistance detection method, genes involved in
164 resistance development, and *mcr* gene screening status. For further analysis, the data were
165 tabulated in a Microsoft Excel sheet.

166 **Subgrouping of data**

167 The research articles with Pol^R reports were classified into two groups based on criteria such
168 as sample size (more than one) and the involvement of *mcr* genes in the development of Pol^R.
169 Studies reporting a specific number of samples containing both Pol^R and susceptible isolates
170 and a particular number of Pol^R bacteria as events were placed in the first group. This group
171 was further subdivided based on the States or UTs from where they were reported. In this
172 classification system, those States were included that have at least four different reports on
173 Pol^R isolates. In the second group, those reports were included where *mcr* gene screening
174 status was mentioned clearly in the study.

175 **Quality assessment**

176 The quality of all eligible reports was determined by the Newcastle–Ottawa Scale (NOS) and
177 only the high-quality reports were considered for the present meta-analysis. According to the
178 NOS guidelines, qualitative scores are given as stars, and a total score of five stars or more
179 for a study is considered a high-quality report.

180 **Meta-analysis**

181 To measure relative risk, we included articles reporting the prevalence of Pol^R bacteria and
182 the contribution of *mcr* genes in this meta-analysis. All statistical analyses were performed
183 using Comprehensive Meta-Analysis (CMA) software (version 4.0; Biostat Inc. USA). The
184 generated data were visualized using forest plots. Publication bias in the included studies was
185 assessed using funnel plots with visual analysis³⁴ and Egger regression analysis³⁵. The
186 heterogeneity of the studies was examined using the Cochrane Q statistics³⁶ and I² statistics
187³⁷. Based on the outcome of the heterogeneity analysis, a fixed-effect model (homogenous) or
188 random-effect model (heterogeneous) was used for the meta-analysis.

189 Overall, 43 articles reporting the prevalence of Pol^R isolates in India were subjected to meta-
190 analysis, whereas 58 reports were included to decipher the role of *mcr* gene in the polymyxin
191 resistance phenotype. Of the 58 reports of *mcr* contribution to Pol^R, 41 were eligible for the
192 meta-analysis. The combined event rate and 95% confidence interval were calculated to
193 determine the frequency of Pol^R isolates in India and the contribution of *mcr* to polymyxin
194 resistance. In addition, sensitivity analysis was performed to explore the robustness of the
195 meta-analysis by excluding one study at a time, performing the meta-analysis, and comparing
196 it with the results of the parent analysis.

197 **RESULT**

198 **Literature review and screened results**

199 Overall, 1408 articles were obtained by searching different databases with suitable keywords
200 (PubMed = 802, Google Scholar = 431, Science Direct = 109, Scopus = 66). The article
201 selection approach is presented in a PRISMA flow chart (Fig. 1). A total of 43 eligible
202 articles reporting Pol^R (Supplementary Table 1) and 41 articles reporting the contribution of
203 *mcr* (Supplementary Table 2) were included in the meta-analysis after careful screening
204 according to the stipulated inclusion and exclusion criteria.

205 **Publication bias**

206 Visual analysis of the funnel plot and Egger's regression analysis showed the absence of
207 publication bias in the analysis of the incidence of Pol^R bacteria in India (intercept: 0.63, 95%
208 CI = -2.38 to 3.65, p = 0.67), as well as in the analysis of the role of *the mcr* gene in Pol^R
209 (intercept: -1.3, 95% CI = -2.69 to 0.08, p = 0.065) (Table 1) (Supplementary Fig. 1).

210 Furthermore, after the categorization of all studies according to the states from which they
211 were reported, the funnel plot and Egger's regression analysis revealed no significant biases

212 while analysing the incidence of Pol^R bacteria in states such as Tamil Nadu, Uttar Pradesh,
213 Odisha, West Bengal, and Delhi (Table 1) (Supplementary Fig. 2).

214 **Heterogeneity analysis**

215 Cochran Q and I² measurements demonstrated significant heterogeneity among the included
216 studies. Hence, a random-effects model was used for all meta-analyses (Table 1).

217 **Prevalence of Pol^R bacteria in India**

218 After investigating 43 reports, the present meta-analysis found that the rate of Pol^R bacteria in
219 India was 15.7% (Fig. 2). Out of 28 states and eight UTs in India, 12 states and 3 UTs have
220 reported the presence of Pol^R bacterial strains. Among all the states that have reported Pol^R,
221 Tamil Nadu, Uttar Pradesh, and Odisha are the top three, where the rate of Pol^R is higher than
222 the Indian average at 32.4%, 16.3%, and 15.9%, respectively. Upon State-wise analysis,
223 Delhi and West Bengal showed significant cases of Pol^R at 13.5%, and 10.9%, respectively,
224 though less than the national average (Fig. 3).

225 **Role of *mcr* gene in the development of Pol^R**

226 Furthermore, to understand the prevalence of *mcr* genes in Pol^R bacterial isolates in
227 comparison with other possible mechanisms in India, 41 reports with positive *mcr* gene
228 screening status and a sample size of more than one (Pol^R isolate) criterion were considered
229 for the analysis (Supplementary Table 2). The meta-analysis results showed that the
230 contribution of the *mcr* gene to the rise in polymyxin resistance was 8.6% in India (Fig. 4).

231 **Sensitivity analysis**

232 Sensitivity analysis was performed to measure the robustness of the meta-analysis by
233 excluding a single study each time and relating the results to the parental meta-analysis. As
234 illustrated in Supplementary Fig. 3, no significant deviation was observed in the sensitivity
235 analysis compared with the original meta-analysis results for studying the incidence of Pol^R
236 bacteria in India. Furthermore, a meta-analysis on the contribution of the *mcr* gene to Pol^R
237 also revealed a robust observation, as shown in Supplementary Fig. 4.

238 **DISCUSSION**

239 The current meta-analysis systematically evaluated the incidence of Pol^R bacteria in India,
240 which was higher than the global average. In this study, we found that 15.7% of GNB were
241 Pol^R, whereas the global average remained at 10%³⁸. A previous study has put the rate of
242 Pol^R among clinical *Enterobacteriaceae* isolates in India at 13.8%³⁹.

243 The present study revealed that GNB resistant to the last line of therapeutics is spread all over
244 India, and States like Tamil Nadu, Uttar Pradesh, and Odisha have a higher incidence of Pol^R
245 strains than the national average. The rising incidence of polymyxin resistance in India could
246 be attributed to their indiscriminate use in the healthcare sector, in poultry farms as growth
247 promoters, and the rapid dissemination of *mcr* genes via horizontal gene transfer. Even
248 though India has banned the use of colistin in animal feeds since 2019, its implications on the
249 spread of Pol^R may be revealed a few years down the line. Interestingly, there are no reports
250 of Pol^R in 16 states and 5 UTs in India, which may be due to the lack of surveillance in those
251 States and UTs. The overall spread of Pol^R GNB in India is shown in Fig. 5A.

252 Although most of the reports used in this study indicated Pol^R rates under 20%, there are a
253 few that have reported significantly higher Pol^R rates^{40–45}. These discrepancies are due to the
254 different methodologies adopted for determining polymyxin resistance. In India, various
255 methods such as the Kirby-Bauer disk diffusion test, broth microdilution (BMD), agar
256 dilution, E-test, VITEK-2, gradient diffusion, colistin broth disc elution, rapid polymyxin
257 Nordmann Poirel Test, Mikrolatest kit, BD Phoenix M50, MicroScan WalkAway 96 Plus,
258 Micronaut-S and Modified Stokes DDT, have been used. However, as per the
259 recommendation of the CLSI and EUCAST, BMD is the only approved method for
260 determining colistin susceptibility^{46,47}, and therefore in this study, the colistin resistance
261 reports determined using the BMD method have only been included.

262 Meta-analysis revealed that in 8.6% of cases, the *mcr* gene was responsible for spreading the
263 Pol^R phenotype in India. In India, after the first detection of the *mcr* gene in a clinical *E. coli*
264 isolate⁴⁸, several reports of *mcr* occurrence have been published^{30,32,49–51}. To date, six
265 classes of *mcr* have been reported in India: *mcr-1*, *mcr-2*, *mcr-3*, *mcr-4*, *mcr-5*, and *mcr-9*. Of
266 the 115 *mcr* variants detected till date, *mcr-1* was the predominant variant responsible for
267 driving polymyxin resistance in India. In the current study, the frequency of *mcr-1* was 72%,
268 whereas the frequencies of *mcr-2*, *mcr-3*, *mcr-4*, *mcr-5*, and *mcr-9* were 3%, 19%, 3%, 1%,
269 and 2%, respectively (Fig. 5C). Considering that *mcr-1* was the first plasmid-borne colistin
270 resistance gene to be detected²⁰ it has spread globally in the last 6-7 years.

271 Unlike the distribution of Pol^R GNB, the spread of *mcr* has been limited to nine states and
272 two UTs in India (Fig. 5B). Among these states, Uttar Pradesh was found to be the hotspot
273 for the spread of *mcr* variants, with 48 reports, followed by Tamil Nadu and Assam with 31
274 and 15 *mcr* variant reports, respectively. However, several reports on Pol^R have not provided
275 sufficient information on *mcr* gene screening status. The limited screening for *mcr* genes

276 among these studies may be responsible for the low rate of detection and reporting of *mcr*
277 genes in India.

278 As mentioned previously, *mcr* genes are largely plasmid-borne, and various types of plasmids
279 are involved in carrying *mcr* genes in GNB^{27,52}. In India, different *mcr* variants were found
280 to be linked with plasmids including IncHI2, IncHI2A, IncX1, IncX4, and FIA Inc^{32,41,53}.
281 The association of these plasmids with other antibiotic-resistance genes conferring resistance
282 to carbapenems, cephalosporins, and fosfomycin has also been previously established^{54,55}.
283 Although plasmids are the primary genetic vehicle through which *mcr* genes disseminate
284 among bacterial species, their chromosomal integration has also been reported in different
285 bacterial species in India⁵⁶⁻⁵⁹. The major advantage of chromosomal integration of *mcr* genes
286 could be their reduced chance of loss from the genome, in the absence of polymyxin
287 selection. Interestingly, some naturally resistant bacteria also harbour the *mcr* genes and can
288 potentially spread them to the polymyxin-susceptible species in the environment⁶⁰.
289 Moreover, few studies have reported the presence of the *mcr-1*, *mcr-3*, and *mcr-9* genes in
290 bacterial species that are susceptible to polymyxin^{51,61}. This is primarily due to the
291 insertional inactivation of *mcr-1* and *mcr-3* genes^{51,61}. However, in the case of *mcr-9* positive
292 *Enterobacter hormaechei* strain, *qseBC* TCS genes were absent downstream⁶² which has
293 been previously described to induce the colistin resistance phenotype by upregulating the
294 *mcr-9* gene expression in response to the subinhibitory concentration of colistin⁶³.

295 This meta-analysis has certain limitations. First, the current study included articles available
296 in the English language only, as a result, publications in other languages have been excluded.
297 Second, we searched reports from databases including PubMed, Google Scholar, Scopus, and
298 Science Direct, so may have missed publications indexed in other databases. Third, as certain
299 Gram-negative bacterial species are inherently resistant to polymyxins, reports on polymyxin
300 resistance from the environmental strains may have been biased toward such species.

301 **CONCLUSION**

302 The present study found that the rate of Pol^R bacterial strains in India was 15.7%, which is
303 higher than the global average. While Pol^R strains have been reported from most of the Indian
304 States and UTs, there are still regions where adequate data are not available, warranting
305 monitoring and surveillance. This study further found that in 8.6% of Pol^R strains, the
306 phenotype was determined by *mcr* genes carried on plasmids. This may be grossly
307 underestimated due to the lack of *mcr* surveillance data in many published articles. As

308 polymyxins are one of the last option antibiotics available against Gram-negative bacterial
309 pathogens, preservation of their antibiotic properties is paramount. However, the increasing
310 incidence of polymyxin resistance in clinics and the environment has the potential to limit
311 antibiotic treatment options. Therefore, along with developing better versions of polymyxins
312 and/or their derivatives, it is also important to devise strategies for monitoring the frequency
313 of Pol^R bacterial species and, the prevalence of *mcr* genes in them. Sustained measures need
314 to be in place to contain the further spread of the polymyxin resistance phenotype in the near
315 future.

316 **Author Contributions**

317 Conceptualization: SKD, AKP, and SSM; Data extraction and analysis: SKD, IP, AKP, and
318 SSM; Data validation: SKD and IP; Manuscript writing and reviewing: SKD, AKP, and
319 SSM. All authors agreed to the submitted version.

320 **Funding**


321 This work is supported by the funds received from the Science and Technology Department,
322 Govt. of Odisha (Grant no. ST-BT-MISC-0005-2023-2463/ST, dt. 23-05-2023).
323 Infrastructure support from the “Centre of Excellence on Bioprospecting of Ethno-
324 pharmaceuticals of Southern Odisha (CoE-BESO)” to the Dept. of Biotechnology,
325 Berhampur University is gratefully acknowledged. Indira Padhy is a recipient of the “Biju
326 Patnaik Research Fellowship (BPRF)” from the Science and Technology Department, Govt.
327 of Odisha.

328 **Conflict of interest**

329 The authors declare that the research was conducted in the absence of any commercial or
330 financial relationships that could be construed as a potential conflict of interest.


331

332 **Figures**




333

334 **Figure 1.** The PRISMA flow diagram for the selection, inclusion, and exclusion of studies.




335

336 **Figure. 2.** Forest plots demonstrating the event rate of polymyxin-resistant (Pol^R) bacteria in
 337 India. The Comprehensive meta-analysis software V4 (Biostat Inc. USA) was used for the
 338 calculation of the event rate and 95% confidence interval.




339

340 **Figure. 3.** Forest plots representing the event rate of polymyxin-resistant (Pol^R) bacteria in
 341 different states of India (A) Delhi, (B) Odisha, (C) Tamil Nadu, (D) Uttar Pradesh, and (E)
 342 West Bengal.



343

344 **Figure. 4.** Forest plots demonstrating the contribution of the *mcr* genes in the development
 345 of polymyxin resistance in India.



346

347 **Figure 5.** (A) Distribution of polymyxin-resistant (Pol^R) bacteria across different States and
348 Union Territories (UTs) of India from 43 studies, (B) Spread of *mcr* genes across different
349 States and UTs of India, and (C) Pie chart showing the percentage of reported *mcr* variants in
350 India.

351 **Table 1.** Statistics to test the publication bias and heterogeneity.

Study Name (Incidence of Pol ^R bacteria)	Egger's Regression Analysis			Heterogeneity Analysis			Model Used
	Intercept	95% Confidence Interval	P Value (2 tailed)	Q value	P- Heterogeneity	I ² (%)	
India	0.63	-2.38 to 3.65	0.67	1603.03	0.00	97.38	Random
Delhi	-6.54	-21.94 to 8.86	0.30	166.14	0.00	96.99	Random
Odisha	2.05	-5.52 to 9.62	0.49	83.95	0.00	94.04	Random
Tamil Nadu	1.84	-8.4 to 12.07	0.68	169.16	0.00	95.27	Random
Uttar Pradesh	0.72	-13.49 to 14.93	0.9	102.7	0.00	94.16	Random
West Bengal	-5.63	-26.41 to 15.15	0.36	81.70	0.00	96.33	Random
<i>mcr</i> gene involvement in Pol ^R	-1.3	-2.69 to -0.08	0.06	129.71	0.00	69.93	Random

371 **Table 2.** Detailed information on the *mcr* gene reported from India.

<i>mcr</i> gene	Plasmid/ Chromosomal	Bacteria	Source	References
<i>mcr-9</i>	Chromosomal	<i>Enterobacter hormaechei</i>	Clinical isolates	#Seethalakshmi et al., 2024 ⁶²
<i>mcr-1.1</i>	IncHI2	<i>E. coli</i> (10)	Clinical isolates	Naha et al., 2023 ⁶⁴
<i>mcr-4</i>	Not determined	<i>Proteus vulgaris</i>	Poultry meat	Premnath et al., 2023 ⁶⁰
<i>mcr-2</i>	Not determined	<i>P. vulgaris</i> , <i>Proteus mirabilis</i>	Poultry meat	Premnath et al., 2023 ⁶⁰
<i>mcr-3</i>	Not determined	<i>Morganella morganii</i> (8), <i>P. vulgaris</i> (3), <i>P. mirabilis</i> (2), <i>Providencia rettgeri</i> (4)	Poultry meat	Premnath et al., 2023 ⁶⁰
<i>mcr-9.1</i>	IncHI2	<i>E. hormaechei</i>	Broiler faeces	Sreejith et al., 2023 ⁵³
<i>mcr-5.1</i>	IncX1	<i>E. coli</i>	Hospital sewage water	Talat et al., 2022 ³⁰
<i>mcr-1</i>	FIA Inc	<i>E. coli</i>	Clinical isolates	Elizabeth et al., 2022 ⁶⁵
<i>mcr-1</i>	Not determined	<i>Klebsiella pneumoniae</i>	Clinical isolates	Bir et al., 2022 ⁶⁶
<i>mcr-1</i> (2)	Plasmid	<i>E. coli</i> (<i>COL^S</i>)*, <i>E. coli</i> (<i>COL^R</i>)	Clinical isolates	Reddy et al., 2022 ⁶¹
<i>mcr-1</i> (19)	Chromosomal, Plasmid	<i>Klebsiella pneumoniae</i> (19)	Clinical isolates	Singh et al., 2021 ⁶⁷
<i>mcr-1</i> (2)	Not determined	<i>E. coli</i> (2)	Clinical isolates	Elizabeth et al., 2021 ⁶⁸

<i>mcr-1</i> (4)	Chromosomal	<i>Pseudomonas aeruginosa</i>	Clinical isolates	Pathak et al., 2020 ⁶⁹
<i>mcr-3.30</i>	Chromosomal	<i>Aeromonas veronii</i> (COL ^S)*	Clinical isolates	Ragupati et al., 2020 ⁵¹
<i>mcr-1</i> (2)	Not determined	<i>E. coli</i>	Clinical isolates	Roy et al., 2020 ⁷⁰
<i>mcr-1</i>	Not determined	<i>K. pneumoniae</i>	Clinical isolates	Roy et al., 2020 ⁷⁰
<i>mcr-1</i> (2)	IncX4	<i>E. coli</i>	Clinical isolates	Soundari et al., 2020 ⁴¹
<i>mcr-1</i> (2)	Not determined	<i>Enterobacter cloacae</i>	Clinical isolates	Mitra et al., 2020 ⁵⁰
<i>mcr-2</i> (3)	Not determined	<i>Burkholderia cepacia</i>	Clinical isolates	Mitra et al., 2020 ⁵⁰
<i>mcr-2</i>	Not determined	<i>Pseudomonas aeruginosa</i>	Clinical isolates	Mitra et al., 2020 ⁵⁰
<i>mcr-1</i>	Not determined	Not mentioned	Clinical isolates	Pathak et al., 2020 ⁵⁸
<i>mcr-1</i> (5)	Plasmid	<i>E. coli</i> , <i>A. veronii</i> , <i>A. dhakensis</i>	Sewage water	Gogry et al., 2019 ³¹
<i>mcr-1</i>	Not determined	<i>E. coli</i>	Clinical isolates	Subramaniam & Muthukrishnan, 2019 ⁷¹
<i>mcr-1</i> (20)	Chromosomal	<i>Acinetobacter baumannii</i>	Clinical isolates	Rahman & Ahmad., 2019 ⁵⁷
<i>mcr-1</i> (3)	IncX1, InCHI2, InCHI2A	<i>E. coli</i>	Poultry and mutton meat	Ghafur et al., 2019 ³²
<i>mcr-1</i> (4)	Chromosomal	<i>K. pneumoniae</i>	Clinical isolates	Singh et al., 2018 ⁵⁶
<i>mcr-1</i>	Not determined	Not mentioned	River sediment	Marathe et al., 2017 ⁴⁹
<i>mcr-1</i>	Plasmid	<i>E. coli</i>	Clinical isolates	Kumar et al., 2016 ⁴⁸
<i>mcr-1</i>	InCHI2	<i>E. coli</i>	Human Stool sample	Bernasconi et al., 2016 ⁷²

372 Species denoted with * mark indicate insertional inactivation of the *mcr* gene, which leads to polymyxin susceptibility. The number
373 mentioned in the brackets represents the number of *mcr* reported. # This paper was published in 2023 as an online early version and
374 therefore included in the study.

375

376 **REFERENCES**

- 377 1. Murray CJ, Ikuta KS, Sharara F, *et al.* Global burden of bacterial antimicrobial resistance
378 in 2019: a systematic analysis. *The Lancet* 2022; S0140673621027240.
- 379 2. O'Neill J. An audience with Jim O'Neill. *Nat Rev Drug Discov* 2016; **15**: 526–526.
- 380 3. Darby EM, Trampari E, Siasat P, *et al.* Molecular mechanisms of antibiotic resistance
381 revisited. *Nat Rev Microbiol* 2023; **21**: 280–95.
- 382 4. Poirel L, Jayol A, Nordmann P. Polymyxins: Antibacterial Activity, Susceptibility Testing,
383 and Resistance Mechanisms Encoded by Plasmids or Chromosomes. *Clin Microbiol Rev*
384 2017; **30**: 557–96.
- 385 5. Mohapatra SS, Dwibedy SK, Padhy I. Polymyxins, the last-resort antibiotics: Mode of
386 action, resistance emergence, and potential solutions. *J Biosci* 2021; **46**: 85.
- 387 6. Benedict RG, Langlykke AF. Antibiotic activity of *Bacillus polymyxa*. *J Bacteriol* 1947;
388 **54**: 24.
- 389 7. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects
390 of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of
391 therapy. *Ann Intern Med* 1970; **72**: 857–68.
- 392 8. Nation RL, Li J. Colistin in the 21st century: *Curr Opin Infect Dis* 2009; **22**: 535–43.
- 393 9. Vaara M. Polymyxins and Their Potential Next Generation as Therapeutic Antibiotics.
394 *Front Microbiol* 2019; **10**: 1689.
- 395 10. Hamel M, Rolain J-M, Baron SA. The History of Colistin Resistance Mechanisms in
396 Bacteria: Progress and Challenges. *Microorganisms* 2021; **9**: 442.
- 397 11. Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and
398 differences from colistin (polymyxin E). *Expert Rev Anti Infect Ther* 2007; **5**: 811–21.
- 399 12. Nang SC, Azad MAK, Velkov T, Zhou Q (Tony), Li J. Rescuing the Last-Line
400 Polymyxins: Achievements and Challenges Barker E, ed. *Pharmacol Rev* 2021; **73**: 679–728.
- 401 13. Olaitan AO, Morand S, Rolain J-M. Mechanisms of polymyxin resistance: acquired and
402 intrinsic resistance in bacteria. *Front Microbiol* 2014; **5**. Available at:
403 <http://journal.frontiersin.org/article/10.3389/fmicb.2014.00643/abstract>. Accessed December
404 8, 2021.
- 405 14. Yu Z, Qin W, Lin J, Fang S, Qiu J. Antibacterial Mechanisms of Polymyxin and Bacterial
406 Resistance. *BioMed Res Int* 2015; **2015**: 1–11.
- 407 15. Antoniadou A, Kontopidou F, Poulakou G, *et al.* Colistin-resistant isolates of *Klebsiella*
408 *pneumoniae* emerging in intensive care unit patients: first report of a multiclonal cluster. *J*
409 *Antimicrob Chemother* 2007; **59**: 786–90.
- 410 16. Lim LM, Ly N, Anderson D, *et al.* Resurgence of Colistin: A Review of Resistance,
411 Toxicity, Pharmacodynamics, and Dosing. *Pharmacotherapy* 2010; **30**: 1279–91.
- 412 17. Elemam A, Rahimian J, Doymaz M. *In Vitro* Evaluation of Antibiotic Synergy for
413 Polymyxin B-Resistant Carbapenemase-Producing *Klebsiella pneumoniae*. *J Clin Microbiol*
414 2010; **48**: 3558–62.
- 415 18. El-Baky RMA, Masoud SM, Mohamed DS, *et al.* Prevalence and Some Possible
416 Mechanisms of Colistin Resistance Among Multidrug-Resistant and Extensively Drug-
417 Resistant *Pseudomonas aeruginosa*. *Infect Drug Resist* 2020; **13**: 323.

- 418 19. Hejnar P, Kolář M, Hájek V. CHARACTERISTICS OF ACINETOBACTER STRAINS
419 (PHENOTYPE CLASSIFICATION, ANTIBIOTIC SUSCEPTIBILITY AND
420 PRODUCTION OF β -LACTAMASES) ISOLATED FROM HAEMOCULTURES FROM
421 PATIENTS AT THE TEACHING HOSPITAL IN OLOMOUC. 1999; **142**.
- 422 20. Liu Y-Y, Wang Y, Walsh TR, *et al.* Emergence of plasmid-mediated colistin resistance
423 mechanism MCR-1 in animals and human beings in China: a microbiological and molecular
424 biological study. *Lancet Infect Dis* 2016; **16**: 161–8.
- 425 21. Ma Q, Huang Y, Wang J, *et al.* Multidrug-resistant *Shigella sonnei* carrying the plasmid-
426 mediated *mcr*-1 gene in China. *Int J Antimicrob Agents* 2018; **52**: 14–21.
- 427 22. Borowiak M, Fischer J, Hammerl JA, Hendriksen RS, Szabo I, Malorny B. Identification
428 of a novel transposon-associated phosphoethanolamine transferase gene, *mcr*-5, conferring
429 colistin resistance in d-tartrate fermenting *Salmonella enterica* subsp. *enterica* serovar
430 Paratyphi B. *J Antimicrob Chemother* 2017; **72**: 3317–24.
- 431 23. Zeng K, Doi Y, Patil S, Huang X, Tian G-B. Emergence of the Plasmid-Mediated *mcr*-I
432 Gene in Colistin-Resistant *Enterobacter aerogenes* and *Enterobacter cloacae*. *Antimicrob*
433 *Agents Chemother* 2016; **60**: 3862–3.
- 434 24. Fernández L, Gooderham WJ, Bains M, McPhee JB, Wiegand I, Hancock REW.
435 Adaptive Resistance to the “Last Hope” Antibiotics Polymyxin B and Colistin in
436 *Pseudomonas aeruginosa* Is Mediated by the Novel Two-Component Regulatory System
437 ParR-ParS. *Antimicrob Agents Chemother* 2010; **54**: 3372–82.
- 438 25. Fernández L, Jenssen H, Bains M, Wiegand I, Gooderham WJ, Hancock REW. The Two-
439 Component System CprRS Senses Cationic Peptides and Triggers Adaptive Resistance in
440 *Pseudomonas aeruginosa* Independently of ParRS. *Antimicrob Agents Chemother* 2012; **56**:
441 6212–22.
- 442 26. Yin W, Li H, Shen Y, *et al.* Novel Plasmid-Mediated Colistin Resistance Gene *mcr*-3 in
443 *Escherichia coli* Bush K, ed. *mBio* 2017; **8**: e00543-17.
- 444 27. Nang SC, Li J, Velkov T. The rise and spread of *mcr* plasmid-mediated polymyxin
445 resistance. *Crit Rev Microbiol* 2019; **45**: 131–61.
- 446 28. Gogry FA, Siddiqui MT, Sultan I, Haq QMohdR. Current Update on Intrinsic and
447 Acquired Colistin Resistance Mechanisms in Bacteria. *Front Med* 2021; **8**: 677720.
- 448 29. Singh S, Pathak A, Rahman M, *et al.* Genetic Characterisation of Colistin Resistant
449 *Klebsiella pneumoniae* Clinical Isolates From North India. *Front Cell Infect Microbiol* 2021;
450 **11**: 666030.
- 451 30. Talat A, Usmani A, Khan AU. Detection of *E. coli* IncX1 Plasmid-Mediated *mcr*-5.1
452 Gene in an Indian Hospital Sewage Water Using Shotgun Metagenomic Sequencing: A First
453 Report. *Microb Drug Resist* 2022; **28**: 759–64.
- 454 31. Gogry FA, Siddiqui MT, Haq. QMohdR. Emergence of *mcr*-1 conferred colistin
455 resistance among bacterial isolates from urban sewage water in India. *Environ Sci Pollut Res*
456 2019; **26**: 33715–7.
- 457 32. Ghafur A, Shankar C, GnanaSoundari P, *et al.* Detection of chromosomal and plasmid-
458 mediated mechanisms of colistin resistance in *Escherichia coli* and *Klebsiella pneumoniae*
459 from Indian food samples. *J Glob Antimicrob Resist* 2019; **16**: 48–52.

- 460 33. Hutton B, Salanti G, Caldwell DM, *et al.* The PRISMA Extension Statement for
461 Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care
462 Interventions: Checklist and Explanations. *Ann Intern Med* 2015; **162**: 777–84.
- 463 34. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on
464 choice of axis. *J Clin Epidemiol* 2001; **54**: 1046–55.
- 465 35. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple,
466 graphical test. *BMJ* 1997; **315**: 629–34.
- 467 36. Higgins JPT, Green S eds. *Cochrane Handbook for Systematic Reviews of Interventions*.
468 The Cochrane Collaboration; 2011. Available at: www.handbook.cochrane.org.
- 469 37. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-
470 analyses. *BMJ* 2003; **327**: 557.
- 471 38. Silva KED, Rossato L, Leite AF, Simionatto S. Overview of polymyxin resistance in
472 Enterobacteriaceae. *Rev Soc Bras Med Trop* 2022; **55**: e0349-2021.
- 473 39. Turnidge JD, Bell JM, Jones RN. Emergence of Colistin-Resistant *Klebsiella* spp., and
474 *Enterobacter* spp. in the Asia-Pacific (APAC) Region: A SENTRY Antimicrobial
475 Surveillance Program Report (2006). In: Washington DC: American Society for
476 Microbiology, 2007.
- 477 40. Bardhan T, Chakraborty M, Bhattacharjee B. Prevalence of Colistin-Resistant,
478 Carbapenem-Hydrolyzing Proteobacteria in Hospital Water Bodies and Out-Falls of West
479 Bengal, India. *Int J Environ Res Public Health* 2020; **17**: 1007.
- 480 41. Palani GS, Ghafur A, Krishnan P, Rayvathy B, Thirunarayan M. Intestinal carriage of
481 colistin resistant Enterobacteriaceae in hospitalized patients from an Indian center. *Diagn*
482 *Microbiol Infect Dis* 2020; **97**: 114998.
- 483 42. Priyanka, Meena PR, Meghwanshi KK, Rana A, Singh AP. Leafy greens as a potential
484 source of multidrug-resistant diarrhoeagenic *Escherichia coli* and *Salmonella*. *Microbiol*
485 *Read Engl* 2021; **167**.
- 486 43. Rohilla R, Raina D, Singh M, Pandita AK, Patwal S. Evaluation of *Sphingomonas*
487 *paucimobilis* as an emerging nosocomial pathogen in a teaching hospital in Uttarakhand. *Iran*
488 *J Microbiol* 2021; **13**: 617–23.
- 489 44. Shanthini T, Manohar P, Hua X, Leptih S, Nachimuthu R. Detection of Hypervirulent
490 *Klebsiella pneumoniae* from Clinical Samples in Tamil Nadu. 2023: 2023.02.19.23286158.
491 Available at: <https://www.medrxiv.org/content/10.1101/2023.02.19.23286158v1>. Accessed
492 September 28, 2023.
- 493 45. Shekhar C, Joshi N, Singh A. Prevalence of Multidrug-Resistant *Escherichia coli* in
494 Drinking-Water in and around Ayodhya (U.P.) , India. *Indian J Vet Sci Biotechnol* 2023; **19**:
495 112–5.
- 496 46. Satlin MJ, Lewis JS, Weinstein MP, *et al.* Clinical and Laboratory Standards Institute and
497 European Committee on Antimicrobial Susceptibility Testing Position Statements on
498 Polymyxin B and Colistin Clinical Breakpoints. *Clin Infect Dis* 2020: cial121.
- 499 47. CLSI. Colistin Breakpoints for *Pseudomonas aeruginosa* and *Acinetobacter* spp. In:
500 Wayne PA, ed. *CLSI Rationale Document MRO1*. 1st ed. Clinical and Laboratory Standards
501 Institute, 2018.
- 502 48. Kumar M, Saha S, Subudhi E. More Furious Than Ever: *Escherichia coli* -Acquired Co-
503 resistance Toward Colistin and Carbapenems. *Clin Infect Dis* 2016: ciw508.

- 504 49. Marathe NP, Pal C, Gaikwad SS, Jonsson V, Kristiansson E, Larsson DGJ. Untreated
505 urban waste contaminates Indian river sediments with resistance genes to last resort
506 antibiotics. *Water Res* 2017; **124**: 388–97.
- 507 50. Mitra S, Basu S, Rath S, Sahu SK. Colistin resistance in Gram-negative ocular infections:
508 prevalence, clinical outcome and antibiotic susceptibility patterns. *Int Ophthalmol* 2020; **40**:
509 1307–17.
- 510 51. Ragupathi NKD, Sethuvel DPM, Anandan S, *et al.* First hybrid complete genome of
511 *Aeromonas veronii* reveals chromosome-mediated novel structural variant mcr-3.30 from a
512 human clinical sample. *Access Microbiol* 2020; **2**. Available at:
513 <https://www.microbiologyresearch.org/content/journal/acmi/10.1099/acmi.0.000103>.
514 Accessed August 17, 2023.
- 515 52. Li Z, Cao Y, Yi L, Liu J-H, Yang Q. Emergent Polymyxin Resistance: End of an Era?
516 *Open Forum Infect Dis* 2019; **6**: ofz368.
- 517 53. Sreejith S, Manjusha P, Prathuish P, *et al.* Predicting human risk with multidrug resistant
518 *Enterobacter hormaechei* MS2 with MCR 9 gene isolated from the feces of healthy broiler
519 through whole genome sequence based analysis. 2023. Available at:
520 <https://www.researchsquare.com>. Accessed September 28, 2023.
- 521 54. Carattoli A, Villa L, Feudi C, *et al.* Novel plasmid-mediated colistin resistance mcr-4
522 gene in *Salmonella* and *Escherichia coli*, Italy 2013, Spain and Belgium, 2015 to 2016.
523 *Eurosurveillance* 2017; **22**. Available at:
524 <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2017.22.31.30589>.
525 Accessed August 24, 2023.
- 526 55. Zurfluh K, Treier A, Schmitt K, Stephan R. Mobile fosfomycin resistance genes in
527 *Enterobacteriaceae*—An increasing threat. *MicrobiologyOpen* 2020; **9**. Available at:
528 <https://onlinelibrary.wiley.com/doi/10.1002/mbo3.1135>. Accessed September 2, 2023.
- 529 56. Singh S, Pathak A, Kumar A, *et al.* Emergence of Chromosome-Borne Colistin
530 Resistance Gene *mcr-1* in Clinical Isolates of *Klebsiella pneumoniae* from India. *Antimicrob*
531 *Agents Chemother* 2018; **62**: e01885-17.
- 532 57. RAHMAN M, Ahmad S. 549. First Report for Emergence of Chromosomal Borne
533 Colistin Resistance Gene *mcr-1* in a Clinical *Acinetobacter Baumannii* Isolates from India.
534 *Open Forum Infect Dis* 2019; **6**: S261–2.
- 535 58. Pathak A, Singh S, Kumar A, Prasad KN. Emergence of chromosome borne colistin
536 resistance gene, *mcr-1* in clinical isolates of *Pseudomonas aeruginosa*. *Int J Infect Dis* 2020;
537 **101**: 22.
- 538 59. Seethalakshmi PS, Prabhakaran A, Kiran GS, Selvin J. First Report on the Circulation of
539 *mcr-9* Bearing *Enterobacteriaceae* Isolated in a Rural Environmental Water Body of India.
540 *SSRN Electron J* 2022. Available at: <https://www.ssrn.com/abstract=4280949>. Accessed
541 August 17, 2023.
- 542 60. Premnath MAC, Prabhakaran K, Sivasankar S, Boppe A, Sriramajayam L, Jeyaraj S.
543 Occurrence of *mcr* genes and alterations in *mgrB* gene in intrinsic colistin- resistant
544 *Enterobacteriales* isolated from chicken meat samples. *Int J Food Microbiol* 2023; **404**:
545 110323.
- 546 61. Reddy BRC, Geetha RV, Singh M, Rani RU, Nekkanti KN. *Mcr-1* expression in
547 progression of colistin resistance gram negative bacilli of clinical specimens derived from

- 548 Intensive Care Units, wards and hospital setting of Deccan Eco Region of Southern India. *J*
549 *Pharm Negat Results* 2022; **13**.
- 550 62. Seethalakshmi PS, Ru VPN, Prabhakaran A, *et al*. Genomic investigation unveils high-
551 risk ESBL producing Enterobacteriaceae within a rural environmental water body. *Curr Res*
552 *Microb Sci* 2024; **6**: 100216.
- 553 63. Kieffer N, Royer G, Decousser J-W, *et al*. *mcr-9*, an Inducible Gene Encoding an
554 Acquired Phosphoethanolamine Transferase in *Escherichia coli*, and Its Origin. *Antimicrob*
555 *Agents Chemother* 2019; **63**: e00965-19.
- 556 64. Naha S, Basak P, Sands K, *et al*. Carriage and within-host diversity of *mcr-1.1*-
557 harbouring *Escherichia coli* from pregnant mothers: inter- and intra-mother transmission
558 dynamics of *mcr-1.1*. *Emerg Microbes Infect* 2023; **12**: 2278899.
- 559 65. Elizabeth R, Baishya S, Kalita B, *et al*. Colistin exposure enhances expression of *eptB* in
560 colistin-resistant *Escherichia coli* co-harboring *mcr-1*. *Sci Rep* 2022; **12**: 1348.
- 561 66. Bir R, Gautam H, Arif N, *et al*. Analysis of colistin resistance in carbapenem-resistant
562 *Enterobacterales* and XDR *Klebsiella pneumoniae*. *Ther Adv Infect Dis* 2022; **9**:
563 204993612210806.
- 564 67. Singh S, Pathak A, Rahman M, *et al*. Genetic Characterisation of Colistin Resistant
565 *Klebsiella pneumoniae* Clinical Isolates From North India. *Front Cell Infect Microbiol* 2021;
566 **11**: 666030.
- 567 68. Elizabeth R, Wangkheimayum J, Singha KM, Chanda DD, Bhattacharjee A.
568 Subinhibitory concentration stress of colistin enhanced PhoPQ expression in *Escherichia coli*
569 harboring *mcr-1*. *J Basic Microbiol* 2021; **61**: 1029–34.
- 570 69. Pathak A, Singh S, Prasad N, Prasad KN. SAT-423 EMERGENCE OF blaNDM AND
571 *mcr-1* POSITIVE PAN- AND EXTREMELY- DRUG RESISTANT BACTERIAL
572 INFECTIONS IN PATIENTS WITH RENAL DISEASES. *Kidney Int Rep* 2020; **5**: S176–7.
- 573 70. Roy S, Das P, Das S, *et al*. Detection of the emergence of *mcr-1* –mediated colistin-
574 resistant *Escherichia coli* and *Klebsiella pneumoniae* through a hospital-based surveillance in
575 an oncology center in eastern India. *Infect Control Hosp Epidemiol* 2020; **41**: 378–80.
- 576 71. Subramaniam N, Muthukrishnan A. Oral mucositis and microbial colonization in oral
577 cancer patients undergoing radiotherapy and chemotherapy: A prospective analysis in a
578 tertiary care dental hospital. *J Investig Clin Dent* 2019; **10**. Available at:
579 <https://onlinelibrary.wiley.com/doi/10.1111/jicd.12454>. Accessed August 17, 2023.
- 580 72. Bernasconi OJ, Kuenzli E, Pires J, *et al*. Travelers Can Import Colistin-Resistant
581 Enterobacteriaceae, Including Those Possessing the Plasmid-Mediated *mcr-1* Gene.
582 *Antimicrob Agents Chemother* 2016; **60**: 5080–4.
- 583